Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer

Table 3 Pathological evaluation of response in group immune checkpoint inhibitor and group non-immune checkpoint inhibitor, n (%)

Variable	Group ICI (n = 53)	Group non-ICI (n = 29)	P value
pCR	7 (13.2)	0 (0.0)	0.048
MPR	19 (35.8)	4 (13.8)	0.041
ypT0	8 (15.1)	0 (0.0)	0.046
ypN0	25 (47.2)	10 (34.5)	0.267
TRG1a	7 (13.2)	0 (0.0)	0.030
TRG1b	12 (22.6)	4 (13.8)	-
TRG2	23 (43.4)	14 (48.3)	-
TRG3	11 (20.8)	11 (39.7)	-

ICI: Immune checkpoint inhibitor; pCR: Pathologic complete response; MPR: Major pathologic response; ypT0: y pathological tumor stage 0; ypN0: y pathological node stage 0; TRG: Tumor regression grading.